Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT02899052
- Locations
- 🇺🇸
Oncology Hematology Associates (OHA) - Springfield /ID# 218855, Springfield, Missouri, United States
🇺🇸University of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 218336, Dallas, Texas, United States
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 25
- Registration Number
- NCT02877550
- Locations
- 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭Universitaetsspital Basel, Basel, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT02846623
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
- Conditions
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 41
- Registration Number
- NCT02758665
- Locations
- 🇩🇪
BAG Onkologische Gemeinschaftspraxis, Dresden, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
🇩🇪Universitätsklinikum Freiburg, Freiburg, Germany
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 234
- Registration Number
- NCT02756897
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 258
- Registration Number
- NCT02756611
- Locations
- 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 147462, Toronto, Ontario, Canada
🇵🇹IPO Porto FG, EPE /ID# 147389, Porto, Portugal
🇨🇭Hopitaux Universitaires de Geneve /ID# 147930, Genève, Geneve, Switzerland
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 291
- Registration Number
- NCT02755597
- Locations
- 🇫🇷
CHU Limoges - Dupuytren 1 /ID# 149292, Limoges CEDEX 1, Franche-Comte, France
🇮🇹Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 148942, Ancona, Italy
🇦🇺Box Hill Hospital /ID# 149112, Box Hill, Victoria, Australia
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 155
- Registration Number
- NCT02689440
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT02670044
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
🇫🇷Institut Paoli Calmettes, Marseille, France
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02640833
- Locations
- 🇺🇸
Site Reference ID/Investigator# 148562, Harvey, Illinois, United States
🇺🇸Site Reference ID/Investigator# 147922, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.